{"nctId":"NCT02089113","briefTitle":"OTX-14-003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery","startDateStruct":{"date":"2014-04","type":"ACTUAL"},"conditions":["Post-Surgical Ocular Pain","Post-Surgical Ocular Inflammation"],"count":241,"armGroups":[{"label":"OTX-DP","type":"EXPERIMENTAL","interventionNames":["Drug: Dexamethasone"]},{"label":"PV","type":"PLACEBO_COMPARATOR","interventionNames":["Procedure: Placebo Vehicle"]}],"interventions":[{"name":"Dexamethasone","otherNames":[]},{"name":"Placebo Vehicle","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Has a cataract and is expected to undergo clear corneal cataract surgery with phacoemulsification and implantation of a posterior chamber lens\n* Has a potential post-operative pinhole corrected Snellen VA of at least 20/200 or better in both eyes\n\nExclusion Criteria:\n\n* Any intraocular inflammation in the study eye present during the screening slit lamp examination\n* Score greater than \"0\" on the Ocular Pain Assessment in the study eye at Screening\n* Any intraocular inflammation in the study eye present during the screening slit lamp examination","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With an Absence of Anterior Chamber Inflammation","description":"Absence of cells (i.e., score of '0') in the anterior chamber of the study eye at Day 14","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With an Absence of Ocular Pain","description":"Absence of pain (i.e., score of '0') in the study eye at Day 8","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"124","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":160},"commonTop":[]}}}